Perimeter Medical Imaging AI on FDA Clearance, AI-Assisted Surgery and 2026 Catalysts

Why It Matters

The clearance gives Perimeter a regulatory foothold in a market desperate for tools that lower re‑excision rates, potentially unlocking significant revenue as hospitals adopt AI‑assisted surgery. Its 2026 catalysts could accelerate investor interest and commercial rollout.

Key Takeaways

• FDA cleared Claire OCT system for real-time cancer surgery imaging
• AI acts as screening tool; surgeon retains final decision
• System currently US-only, not sold internationally
• 2026 catalysts include conference presentation and market expansion plans
• Goal: reduce re-excision rates and improve oncology outcomes

Pulse Analysis

The FDA’s approval of Perimeter’s Claire OCT system marks a pivotal moment for intra‑operative imaging, a segment long plagued by limited real‑time feedback. Surgeons traditionally rely on frozen sections or postoperative pathology, which can miss residual tumor tissue and lead to costly re‑operations. By delivering ultra‑high‑resolution optical coherence tomography images instantaneously, Claire offers a tangible method to assess margins on the spot, aligning with broader industry pushes toward precision oncology and value‑based care.

Claire’s architecture blends optical coherence tomography hardware with proprietary artificial intelligence that flags suspicious tissue, yet it deliberately stops short of diagnostic authority. This human‑AI partnership respects regulatory boundaries while enhancing surgeon confidence, a model gaining traction as regulators favor decision‑support rather than autonomous diagnostics. Although the device is limited to the U.S. market for now, its clearance paves the way for future submissions abroad, especially in Canada and Europe where similar unmet needs exist.

Looking ahead, Perimeter’s 2026 roadmap hinges on several catalysts: a showcase at the Planet MicroCap Las Vegas event, potential partnerships with major hospital systems, and the rollout of complementary software modules that could broaden the device’s applicability beyond breast cancer to other solid tumors. If the company can translate its regulatory win into sustained adoption, it stands to capture a sizable slice of the global surgical imaging market, projected to exceed $5 billion by the early 2030s. Investors will be watching revenue traction, reimbursement pathways, and the company’s ability to scale manufacturing as key risk indicators.

Original Description

In this interview, Adrian Mendes, CEO of Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF), discusses the company's technology for improving cancer surgery outcomes, recent milestones including FDA approval, and upcoming value catalysts for 2026 and beyond.

Chapters

00:00 Introduction to Perimeter Medical Imaging AI

02:22 Understanding the Problem in Cancer Surgeries

03:46 Technological Innovations and FDA Approval

06:39 Value Catalysts for Growth in 2026 and Beyond

09:53 Conclusion and Future Outlook

Perimeter Medical Imaging AI, Inc. will be presenting at the upcoming Planet MicroCap Las Vegas 2026 powered by MicroCapClub. Register to attend here: https://www.meetmax.com/sched/event_130817/conference_home.html

For more information about Perimeter Medical Imaging AI, Inc., please visit: https://perimetermed.com/

The interview may contain forward looking statements about Perimeter Medical Imaging AI, Inc. See Perimeter Medical Imaging AI, Inc.'s periodic filings with SEDAR and the Securities and Exchange Commission for more complete information.

About Perimeter Medical Imaging AI, Inc.

Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Claire™, recently approved by the U.S. Food and Drug Administration (FDA), is our next-generation AI-enabled device. The Company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Note:

The Claire OCT System is an adjunctive tool; it does not replace standard tissue histopathology nor provide a diagnosis. Claire is not available for sale outside the USA.

ImgAssist AI does not itself diagnose a margin as positive or negative. The Claire OCT system is designed as a human-AI team, where the AI acts as a screening tool and the surgeon provides clinical judgment.

The efficacy of Claire was evaluated only after completion of standard of care (SOC). For more information, refer to https://clinicaltrials.gov/study/NCT05113927.

Planet Microcap hosts the highest quality in-person microcap events in North America. The mission is to bring the best microcap investors, companies, and allocators together to gather, connect, and grow.; visit https://planetmicrocap.com/ to learn more about our Las Vegas and Toronto events.

This presentation is for informational purposes only and should not be construed as a recommendation to purchase or sell any security referenced herein. Planet MicroCap Holdings LLC and MicroCapClub LLC (collectively, “we” or “our”) are not licensed brokers nor registered investment advisors. We, our partners, contractors, members, subscribers, guests, or affiliates may or may not hold positions in one or more of the securities mentioned in this presentation and may trade in such securities at any time. We may have received cash compensation from one or more participants for presenting at past, present, or future events. We recommend you consult a licensed investment adviser, broker, or legal counsel before purchasing or selling any securities referenced in this presentation.